Table of Contents What the WHOs New Guideline Says Why This Matters for Diabetes Care Clinical and Practical Considerations Looking Ahead: Diabetes Care and Chronic Obesity Management Conclusion FAQs What the WHOs New Guideline Says In December 2025, the World Health Organization released its first-ever guideline recommending GLP1 therapies for adults with obesity
These insights can support more informed conversations with your provider about whether starting .25 semaglutide aligns with your genetic predispositions and whether dose escalation may be more or less likely to be effective for you
The company has faced a wave of state-level lawsuits challenging whether its sports contracts amount to unlicensed gambling operations
Bottom line The safety signal linking GLP-1 drugs to rare cases of so-called stomach paralysis is strong enough to warrant close attention, but current evidence does not yet prove a direct cause-and-effect relationship
Our experienced team, personalized approach, and comprehensive support system make them the ideal partner in your weight loss journey
First dose about 2 days from intake Each pillar scored 0 to 10, equal-weighted